Phase II trial of pembrolizumab and epacadostat in recurrent clear cell carcinoma of the ovary: An NRG oncology study GY016-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Phase II trial of pembrolizumab and epacadostat in recurrent clear cell carcinoma of the ovary: An NRG oncology study GY016

Published:2024-07 Issue: Volume:186 Page:61-68
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Gien Lilian T.,Enserro Danielle M.,Block Matthew S.,Waggoner Steven,Duska Linda R.,Wahner-Hendrickson Andrea E.,Thaker Premal H.,Backes Floor,Kidd Michael,Muller Carolyn Y.,DiSilvestro Paul A.,Covens Allan,Gershenson David M.,Moore Kathleen N.,Aghajanian Carol,Coleman Robert L.

Funder

National Institutes of Health

Publisher

Elsevier BV

Reference25 articles.

1. Clear cell carcinoma of the ovary: a report from the first ovarian clear cell symposium;Anglesio;Gynecol. Oncol.,2011

2. Low response rate of second-line chemotherapy for recurrent or refractory clear cell carcinoma of the ovary: a retrospective Japan clear cell carcinoma study;Takano;Int. J. Gynecol. Cancer,2008

3. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: interim results from the phase II KEYNOTE- 100 study;Matulonis;Ann. Oncol.,2019

4. Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer;Hamanishi;J. Clin. Oncol.,2015

5. Efficacy and safety of avelumab for patients with recurrent or refractory ovarian cancer: phase 1b results from the JAVELIN solid tumor trial;Disis;JAMA Oncol.,2019

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP